

BERNARDS ET AL.
Appl. No. 10/587,023
Atty Ref.: 620-445
Amendment After Final Rejection
February 11, 2010

AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

1. (Currently Amended) A method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid,

 said inhibitor of PRAME being an interfering RNA (RNAi);

said inhibitor of HDAC being selected from the group consisting of trichostatin A (TSA), trapoxin, suberoylanilide hydroxamic acid (SAHA), phenylbutyrate, a diallyl sulphide, oxamflatin, MS-27-275, PXD101, a butyrate derivative, FR901228, depudecin, m-carboxy cinnamic acid bishydroxamide, a carbamic acid compound comprising a sulphonamide linkage, a carbamic acid compound comprising an ether linkage, a carbamic acid compound comprising an amide linkage and a carbamic acid compound comprising a piperazine linkage; and

said tumour being selected from the group consisting of a melanoma, an acute leukemia, a chronic leukemia, a non-small-cell lung carcinoma, a head cancer, a neck cancer, a renal carcinoma and a breast cancer.

2. (Original) The method of claim 1, wherein the inhibitor of PRAME is an siRNA or vector encoding said siRNA.

3. (Previously Presented) The method of claim 1 wherein said HDACi is N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide.

BERNARDS ET AL.
Appl. No. 10/587,023
Atty Ref.: 620-445
Amendment After Final Rejection
February 11, 2010

4. (Previously Presented) The method of claim 1 wherein said tumour is a melanoma.

5. (Withdrawn) An inhibitor of PRAME and a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid, as a combined preparation for simultaneous, separate or sequential use in therapy.

6. (Withdrawn) An inhibitor and second agent for use according to claim 5 wherein said therapy is treatment of a melanoma.

7. (Withdrawn) An inhibitor and second agent for use according to claim 5 or 6 wherein said inhibitor of PRAME is an siRNA or vector encoding said siRNA.

8. (Withdrawn) An inhibitor and second agent for use according to claim 5, 6 or 7 wherein said HDACi is N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide.

Claims 9-11. (Canceled)

12. (Withdrawn) An assay for an inhibitor of an interaction between PRAME and a retinoic acid receptor (RAR) which comprises bringing together:

- (i) a candidate inhibitor; and
- (ii) a PRAME protein and a RAR protein; and

determining if the putative inhibitor is capable of preventing an interaction between said PRAME and RAR proteins.